Hormone replacement therapy raises the risk of ischemic stroke for some users, but the size of that risk depends heavily on how the hormones are delivered, what dose is used, which type of progestogen is included, and when treatment begins relative to menopause. The landmark Women’s Health Initiative trial found that oral estrogen plus progestin increased stroke risk by roughly 30 to 40 percent in postmenopausal women, and that finding reshaped clinical practice for a generation. But research since then has painted a far more granular picture, one where transdermal patches at standard doses appear not to raise stroke risk at all, where low-dose formulations behave differently from high-dose ones, and where the type of progestogen paired with estrogen may matter as much as the estrogen itself.
What the Women’s Health Initiative Actually Found
The Women’s Health Initiative (WHI) remains the largest randomized trial to examine HRT and cardiovascular outcomes. In the combined estrogen-plus-progestin arm, stroke rates were about 41 percent higher among women on hormones compared with placebo, translating to roughly 8 extra strokes per 10,000 women per year of use.1JAMA. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial A closer look at the stroke-specific data showed the hazard ratio for ischemic stroke was 1.44, while hemorrhagic stroke risk was not significantly increased.2JAMA. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women’s Health Initiative: A Randomized Trial In women aged 65 and older, both estrogen alone and combined therapy were linked to roughly a 50 percent excess risk of ischemic stroke and an even larger increase in dementia risk.3PubMed. Stroke findings in the Women’s Health Initiative
These results landed like a bomb. Millions of women stopped HRT, and prescribing plummeted. But the WHI used one specific formulation: oral conjugated equine estrogens at 0.625 mg daily, combined with medroxyprogesterone acetate. The average age of participants was 63, well past the typical age when women begin HRT for menopausal symptoms. Those details turned out to be crucial, because the decade of research that followed showed the stroke signal is not a blanket property of all hormone therapy. It is tied to specific choices about how hormones are given.
Why the Delivery Route Changes Everything
The single biggest modifier of stroke risk in HRT is whether estrogen reaches the body through a pill or through the skin. Oral estrogen passes through the liver before entering the bloodstream, and this so-called first-pass metabolism triggers changes in clotting proteins that make blood more prone to forming clots. One study demonstrated that estrone, the main metabolite of oral estradiol, ramps up thrombin generation through this hepatic pathway, an effect that transdermal estrogen avoids entirely because it enters the bloodstream directly.4PubMed. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy
The clinical data back this up consistently. A large case-control study found that the adjusted rate ratio for stroke with transdermal estrogen was 0.95, essentially no increase at all, compared with 1.28 for oral estrogen.5PubMed. Transdermal hormone therapy and the risk of stroke and venous thrombosis A national cohort study confirmed that transdermal hormone therapy was not associated with stroke risk.6PubMed. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study And a nested case-control study looking at both routes side by side found that low-dose transdermal patches carried no increased stroke risk at all, with a rate ratio of 0.81, while oral estrogen at both low and high doses raised risk.7BMJ. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
This distinction has reshaped prescribing. For women whose primary concern is stroke risk, transdermal estrogen at a dose of 50 micrograms or less has become the preferred approach. At higher transdermal doses, however, the safety advantage narrows. That same BMJ study found that high-dose patches nearly doubled the risk of stroke, with a rate ratio of 1.89.7BMJ. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study So the route matters, but dose still matters within the transdermal route.
Dose and Its Effect on Risk
Even within oral estrogen, dose makes a difference. Data from the Nurses’ Health Study showed that low-dose oral conjugated estrogen (0.3 mg per day) was not associated with increased stroke risk, unlike the standard 0.625 mg dose used in the WHI.8PubMed Central. Hormone therapy and the risk of stroke: perspectives ten years after the Women’s Health Initiative trials This suggests that the threshold for harm lies somewhere above the lowest available oral doses, though the evidence for ultra-low-dose oral estrogen is thinner than for transdermal delivery.
Clinicians now try to use the lowest effective dose regardless of route. For hot flashes and vaginal symptoms, the dose needed is often lower than what was standard practice twenty years ago. This shift toward minimally effective dosing has likely contributed to a better safety profile for modern HRT regimens, though head-to-head randomized trials comparing dose tiers remain scarce.
Not All Progestogens Are the Same
When estrogen is prescribed for women who still have a uterus, a progestogen is added to prevent endometrial overgrowth. But the type of progestogen turns out to influence stroke risk. A French case-control study found that the risk of ischemic stroke varied significantly by progestogen class. Natural progesterone, pregnane derivatives, and nortestosterone derivatives were not associated with increased ischemic stroke risk. Norpregnane derivatives, however, more than doubled the risk, with an odds ratio of 2.25. The effect was driven largely by one molecule, nomegestrol acetate, which carried an odds ratio of 2.85.9PubMed Central. Postmenopausal Hormone Therapy and Risk of Stroke
Micronized progesterone, which is chemically identical to the progesterone the body produces, has gained popularity partly because of findings like these. A narrative review noted that synthetic progestins have uneven effects on metabolic and cardiovascular systems, while micronized progesterone allows for more physiological effects.10PubMed Central. Estradiol and Micronized Progesterone: A Narrative Review About Their Use as Hormone Replacement Therapy The WHI used medroxyprogesterone acetate, a synthetic progestin. Whether the stroke signal in that trial would have been smaller with micronized progesterone is unknown, because no equivalently large randomized trial has tested the combination. But the observational evidence suggests the progestogen choice is worth discussing with your doctor.
When You Start Matters
The timing hypothesis holds that estrogen protects blood vessels when they are still healthy but can accelerate damage when atherosclerosis has already set in. In younger women with healthy arteries, estrogen promotes nitric oxide production and preserves the ability of blood vessels to dilate, both of which are protective.11PubMed. Estrogen receptors and endothelium But in older women with stiffened, plaque-laden vessels, those same hormonal effects may destabilize plaques or promote clot formation in already narrowed arteries.12PubMed Central. Hormone Therapy and Stroke: Is It All About Timing?
A pooled analysis of population-based cohort studies found that early initiation of estrogen-alone therapy was associated with a longer stroke-free period. Combined HRT initiated long after menopause, by contrast, was associated with a shorter time to both overall stroke and hemorrhagic stroke, although these findings did not all reach statistical significance.13PLOS Medicine. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies This aligns with the broader pattern seen in the WHI, where average enrollment age was 63. For a 51-year-old woman starting HRT at menopause, the absolute risk picture looks very different from the WHI population.
In women aged 50 to 59, the background rate of stroke is about 6 to 8 per 10,000 women per year. Even if HRT raises risk by 40 percent, that translates to only 1 or 2 extra strokes per 10,000 women per year, a rate considered very rare.14PubMed. The risk of stroke in postmenopausal women receiving hormonal therapy For older women, or those who start HRT many years after menopause, the same relative increase lands on a higher baseline rate, making the absolute risk much more meaningful.
An Early Spike in Risk
One often-overlooked finding is that the first few months of HRT use may carry a disproportionate risk. A study of postmenopausal women found that during the first six months of hormone use, the risk of ischemic stroke roughly doubled compared with never-users, even though long-term use in the same study was not associated with a significant increase.15JAMA Internal Medicine. Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women This early spike may reflect the acute prothrombotic shift that oral estrogen triggers before the body adapts, and it underscores the importance of close monitoring when starting therapy.
Pre-existing Conditions That Compound the Risk
HRT does not operate in a vacuum. Among women using HRT, advancing age, smoking, excess body weight, and hypertension all independently increased stroke risk.16PubMed. Risk of stroke and hormone replacement therapy. A prospective cohort study These are the same factors that raise stroke risk in anyone, but they stack on top of whatever incremental risk HRT adds. A healthy 52-year-old non-smoker with normal blood pressure faces a very different risk calculation than a 60-year-old with poorly controlled hypertension and a smoking habit.
Genetic clotting disorders add another layer. Women who carry the factor V Leiden mutation, the most common inherited thrombophilia, may face a particularly elevated stroke risk when using HRT.17PubMed. Is hormone replacement a risk factor for ischemic stroke in women with factor V Leiden mutation? Routine screening for factor V Leiden before starting HRT is not standard practice, but if you have a personal or family history of blood clots, it is worth discussing with your prescriber.
Migraine With Aura Deserves Extra Caution
Migraine with aura is itself an independent risk factor for ischemic stroke. A meta-analysis of over six million participants found that people with migraine with aura had more than twice the stroke risk of those without migraine, while migraine without aura carried a smaller but still elevated risk.18PubMed Central. Considerations for hormonal therapy in migraine patients: a critical review of current practice When estrogen-containing hormonal treatments are layered on top of migraine with aura, the risks compound. One nested case-control study found that the odds ratio for ischemic stroke in women with migraine with aura who used combined hormonal therapy was 6.1.18PubMed Central. Considerations for hormonal therapy in migraine patients: a critical review of current practice Tobacco use pushes the risk even higher.19PubMed. Menopause hormone therapy, migraines, and thromboembolism
The absolute risk of stroke remains low even in this group, but the relative increase is steep enough that many clinicians recommend against oral estrogen for women who have migraine with aura. Transdermal estrogen at low doses and continuous regimens that avoid estrogen fluctuations are sometimes considered alternatives, though the evidence base for that approach is limited.
Vaginal Estrogen Looks Safe
Vaginal estrogen, used primarily for genitourinary symptoms like dryness and recurrent urinary tract infections, delivers much smaller amounts of estrogen into the bloodstream than oral or transdermal formulations. Data from the Nurses’ Health Study found no increased risk of stroke, heart attack, blood clots, or cancer among vaginal estrogen users compared with non-users.20PubMed Central. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
Even in women with a history of prior ischemic stroke, where you might expect heightened sensitivity to any estrogen exposure, vaginal estradiol tablets were not associated with an increased rate of recurrent stroke.21PubMed. Recurrent Ischemic Stroke and Vaginal Estradiol in Women With Prior Ischemic Stroke: A Nationwide Nested Case-Control Study This is reassuring, because genitourinary symptoms are common after menopause and can significantly affect quality of life. Women who have been told to avoid systemic HRT because of stroke risk may still be candidates for vaginal estrogen.
Stroke Severity, Not Just Stroke Rate
Most of the research focuses on whether HRT causes more strokes. Fewer studies have asked whether strokes that occur during HRT are more or less severe. The evidence here is mixed. One small case-control study found a trend toward lesser stroke severity in HRT users, but the difference was not statistically significant.22PubMed. Hormone replacement therapy and ischemic stroke severity in women: a case-control study A meta-analysis of multiple trials, however, found that HRT was associated with a shift toward greater stroke severity when outcomes were categorized as fatal stroke, non-fatal stroke, or no stroke.23European Heart Journal. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis A separate analysis observed a trend toward more fatal strokes and greater dependency after stroke in HRT users, along with a 56 percent increased rate of death or dependency following stroke.24PubMed. Hormone replacement therapy and stroke
These findings are worrying, though none of the individual studies were large enough to be definitive. If HRT both modestly increases stroke incidence and shifts outcomes toward more severe strokes, the combined effect on disability is larger than either number alone suggests. This is an area where more research is badly needed.
What Happens When You Stop
Stopping HRT is not the mirror image of never having started it. A Finnish study found that in the first year after discontinuing HRT, the risk of stroke death was significantly elevated, with a hazard ratio of 1.63. The stroke death risk was even higher when compared directly with women still using HRT, at 2.52.25The Journal of Clinical Endocrinology & Metabolism. Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy After that first year, the excess risk faded and long-term follow-up actually showed a reduced risk. The mechanism behind this rebound is not fully understood, but abrupt estrogen withdrawal may trigger vascular instability or a prothrombotic rebound. If you and your doctor decide to stop HRT, a gradual taper rather than an abrupt stop is the usual recommendation.
What European Guidelines Recommend
The European Stroke Organisation guidelines on stroke in women found low-quality evidence to suggest against using HRT to reduce stroke risk.26PubMed Central. European Stroke Organisation guidelines on stroke in women: Management of menopause, pregnancy and postpartum That phrasing is worth unpacking. It does not say HRT should never be used. It says HRT should not be prescribed for the purpose of preventing stroke, because it does not prevent stroke and may increase the risk depending on the formulation. Using HRT for its intended purpose, managing menopausal symptoms, is a separate clinical decision that involves weighing stroke risk against symptom burden, bone health, and quality of life. The guideline reflects that distinction.
Gender-Affirming Hormone Therapy
Transfeminine individuals who take estrogen as part of gender-affirming hormone therapy face a related but distinct set of questions. A large cohort study found that the patterns of increased blood clots and ischemic stroke in transfeminine persons did not mirror those seen in cisgender women using HRT.27PubMed Central. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study Much of the current safety knowledge for feminizing hormone therapy is drawn from research in cisgender populations, which may not fully apply.28PubMed. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks Estrogen doses used in gender-affirming care are often higher than those used for menopause, and they are typically taken by people who did not grow up with endogenous estrogen exposure, which changes the vascular context. The stroke implications for this population remain an active area of study, and blanket application of findings from postmenopausal HRT trials is not appropriate.
Why Many Women Misjudge the Risk
A systematic review of how menopausal women perceive HRT found that only about 30 percent were aware of potential adverse events, and just 14 percent thought the risks outweighed the benefits. Meanwhile, roughly a third believed the benefits outweighed the risks, and nearly half perceived HRT as effective for symptoms.29PLOS ONE. Knowledge, Perceptions and Information about Hormone Therapy (HT) among Menopausal Women: A Systematic Review and Meta-Synthesis These numbers suggest that most women are making decisions about HRT without a clear picture of its cardiovascular risks, which is a problem that nuanced evidence makes worse, not better. A risk conversation that just says “HRT increases stroke risk” is both too alarming for the low-risk woman on a transdermal patch and too reassuring for the older woman on high-dose oral estrogen with uncontrolled blood pressure. The specifics matter, and they are worth asking about.
Interactions With Blood-Thinning Medications
Women who are already on anticoagulant therapy face a practical wrinkle. One retrospective review found that tibolone, a synthetic HRT preparation, consistently caused acute over-anticoagulation when introduced in women taking oral anticoagulants, requiring dose adjustment to restore safe levels. Other, non-tibolone HRT preparations did not consistently interfere with anticoagulant control.30PubMed. Interaction between hormone replacement therapy preparations and oral anticoagulant therapy If you are on blood thinners and considering HRT, the choice of formulation and close INR monitoring during the transition period are worth planning carefully with both your gynecologist and the clinician managing your anticoagulation.